Individuals carrying genetic variants linked to appetite dysregulation or reduced GLP-1 receptor sensitivity may experience more pronounced therapeutic response to semaglutide, making them excellent candidates regardless of their starting BMI
A small pilot study in 20 human patients (aged 5075, with obesity and knee osteoarthritis) found that those receiving semaglutide alongside standard treatment showed an average 17% increase in cartilage thickness on MRI after 24 weeks, compared to less than 1% in the control group
Nucleic Acids Res 41, D327D332, doi: 10.1093/nar/gks991 (2013)
230 Subsequent studies continue to confirm that hearing loss is strongly correlated with depression and other neuropsychiatric symptoms
Dual agonists that activate both GLP-1 and GIP receptors have been shown to provide more pronounced weight loss, better glycemic control, and better metabolic outcomes compared to GLP-1 RAs alone
Characterization of a novel congenic strain of diabetic fatty (WBN/Kob-lepr(fa)) rat